Compare
Evofem Biosciences, Inc. vs CASI Pharmaceuticals, Inc. vs Sol-Gel Technologies Ltd. vs NewAmsterdam Pharma Co N.V.
| Latest fiscal year | Evofem Biosciences, Inc. EVFM | CASI Pharmaceuticals, Inc. CASIF | Sol-Gel Technologies Ltd. SLGL | NewAmsterdam Pharma Co N.V. NAMS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $20.18M | $20.71M | $19.39M | $22.50M |
| Revenue growth (YoY) | +4.2% | -27.4% | +68.0% | -50.6% |
| Gross margin | 77.1% (computed) | 48.6% | n/a | n/a |
| Operating margin | 16.7% | -217.3% | -38.9% | n/m |
| Net margin | 1.9% | -232.0% | -31.6% | -905.7% |
| Net income | $391.0K | -$48.06M | -$6.13M | -$203.82M |
| EPS (Diluted) | $0.00 | -$2.59 | -$2.19 | -$1.72 |
| Operating cash flow | -$1.99M | -$20.75M | $322.0K | -$147.78M |
| Free cash flow | -$2.00M | -$20.77M | $275.0K | -$148.03M |
| Cash & equivalents | $578.0K | $5.63M | $11.03M | $490.00M |
| Total assets | $20.27M | $25.65M | $29.92M | $769.28M |
| Total liabilities | $89.71M | $62.93M | $7.11M | $85.85M |
| Shareholders' equity | -$74.34M | -$37.28M | $22.81M | $683.43M |
| Return on year-end equity | n/a | n/a | -26.9% | -29.8% |
| Shares outstanding | 126.69M | 20.56M | 2.79M | 114.40M |
Revenue, most recent five fiscal years
| Fiscal year | Evofem Biosciences, Inc. | CASI Pharmaceuticals, Inc. | Sol-Gel Technologies Ltd. | NewAmsterdam Pharma Co N.V. |
|---|---|---|---|---|
| Latest | $20.18M Ended 2025-12-31 | $20.71M Ended 2025-12-31 | $19.39M Ended 2025-12-31 | $22.50M Ended 2025-12-31 |
| 1 year earlier | $19.36M Ended 2024-12-31 | $28.54M Ended 2024-12-31 | $11.54M Ended 2024-12-31 | $45.56M Ended 2024-12-31 |
| 2 years earlier | $18.22M Ended 2023-12-31 | $33.88M Ended 2023-12-31 | $1.55M Ended 2023-12-31 | $14.09M Ended 2023-12-31 |
| 3 years earlier | $16.84M Ended 2022-12-31 | $43.11M Ended 2022-12-31 | $3.88M Ended 2022-12-31 | $102.69M Ended 2022-12-31 |
| 4 years earlier | $8.24M Ended 2021-12-31 | $30.17M Ended 2021-12-31 | $31.27M Ended 2021-12-31 | n/a |